White Paper: Profiling Oncology Drug Candidates Through Complementary in vitro Assays and in vivo Models to Better Understand Their Potential Clinical Applications

White Paper: Profiling Oncology Drug Candidates Through Complementary in vitro Assays and in vivo Models to Better Understand Their Potential Clinical Applications
File Name/Number:
20944

Year:
2019

This white paper describes a profiling strategy that includes both in vitro and in vivo approaches to characterize sorafenib, an ATP-competitive multi-kinase inhibitor with clinical applications in multiple cancer types. Data for vemurafenib, an anti-neoplastic B-Raf kinase inhibitor, is also included to highlight how profiling compounds can shed light onto potentially different applications in the clinic.